Ocugen Inc. (OCGN) News
Filter OCGN News Items
OCGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCGN News Highlights
- OCGN's 30 day story count now stands at 3.
- Over the past 8 days, the trend for OCGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, DEC and AMD are the most mentioned tickers in articles about OCGN.
Latest OCGN News From Around the Web
Below are the latest news stories about OCUGEN INC that investors may wish to consider to help them evaluate OCGN as an investment opportunity.
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study DesignMALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP). “This news brings us even clo |
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO MutationsRMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT desig |
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationMALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the ArMaDa Phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (dAMD). “OCU410, our first-in-class modifier gene therapy for dAMD, addres |
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceMALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking |
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call TranscriptOcugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […] |
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt DiseaseMALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the ret |
Q3 2023 Ocugen Inc Earnings CallQ3 2023 Ocugen Inc Earnings Call |
Ocugen (OCGN) Q3 2023 Earnings Call TranscriptJoining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's chairman, CEO, and co-founder, who will provide a business update and an overview of our clinical and operational progress. Michael Breininger, our corporate controller is also on the call to provide a financial update for the quarter ended September 30, 2023. |
Ocugen Inc (OCGN) Reports Q3 2023 Financial Results and Business UpdatesOcugen Advances Clinical Programs and Maintains Strong Cash Position Amidst Operating Expense Management |
Ocugen Provides Business Update with Third Quarter 2023 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a pediatric patient OCU400 Phase 1/2 study results suggest stabilization or improvement of Best-Corrected Visual Acuity (BCVA) or Multi-Luminance Mobility Testing (MLMT) or Low-Luminance Visual Acuity (LLVA) in treated eyes of 83% (10/12) subjectsStabilization or i |